Publication | Closed Access

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

Surgical OncologyOncologyCancer ManagementIntensified SchedulePathologyChemotherapy-resistant Malignant MesotheliomaAnti-cancer AgentCancer TreatmentMedicineRadiation Oncology